AlzeCure Pharma AB (publ) (AC6.F)
| Previous Close | 0.1600 |
| Open | 0.1600 |
| Bid | 0.1600 x 0 |
| Ask | 0.2150 x 0 |
| Day's Range | 0.1600 - 0.1600 |
| 52 Week Range | 0.1210 - 0.5220 |
| Volume | |
| Avg. Volume | 283 |
| Market Cap | 10.632M |
| Beta (5Y Monthly) | 0.38 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0500 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
ACCESSWIREEli Lilly's and AstraZeneca's Former Head of Research Dr. Jan Lundberg Invests in AlzeCure and is Proposed for Election to its Board
STOCKHOLM, SWEDEN / ACCESSWIRE / April 10, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB ("AlzeCure" or "the Company"), a pharmaceutical company that develops candidate drugs for CNS diseases, focusing on Alzheimer's disease and ...
- ACCESSWIRE
AlzeCure Pharma Publishes its Annual Report for 2023
STOCKHOLM, SE / ACCESSWIRE / April 4, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops a broad portfolio of small molecule candidate drugs for diseases affecting the central ...
- ACCESSWIRE
AlzeCure Presents New Data Regarding the TrkA-NAM Pain Project at IASP 2024
STOCKHOLM, SWEDEN / ACCESSWIRE / April 3, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for CNS diseases, focusing on Alzheimer's disease and pain, today ...
